Abstract: Objective To analyze the efficiency, safety and prognosis of allogeneic stem cell transplantation in patients with multiple myeloma. Methods A retrospective analyze was performed on clinical data of 22 patients from April 2003 to June 2012 who received myeloablative allogeneic stem cell transplantation. The median age of these patients was 44.5 years (range, 28-82 years).All the patients were followed up to October 2012.The median follow-up time was 11 months(range,0.9-92 months). Results The complete remission(CR) rate before and after transplantation was 13.6% and 63.6% respectively. The transplant-related mortality was 9.1% within first 100 days and 22.7% in the first year. The relapse rate of first year was 13.6%. The total survival rate was 68.2% and progression-free rate was 50%.Multivariate analysis showed age, sexuality, remission status and periods between diagnosis and transplantation were not the independent risk factor of prognosis. Conclusion Myeloablative allogeneic stem cell transplantation was an efficient and safety therapy with decreased relapse rate of first year in young patients with multiple myeloma.